Finally, the potent anti-cancer effects in the low micromolar range for PHA-767491 are mediated via potent DDK and CDK2 inhibitory activity that requires further investigation to determine its clinical significance in RB+ tumours. This evidence concerns the gene CDK2 and neoplasm.